Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 7/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143888 | 0.78 | MAPT (0.46) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL2464115 | 0.77 | NOX1 (0.52) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL28481154 | 0.77 | CHRM2 (0.46) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL14199481 | 0.77 | MAPT (0.61) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL15973455 | 0.74 | MAPT (0.58) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| Carbonyl Cyanide M-Chlorophenylhydrazone SCHEMBL379195 | 0.72 | MAPT (1.00) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| Carbonyl Cyanide M-Chlorophenylhydrazone SCHEMBL29353613 | 0.72 | MAPT (1.00) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL10335995 | 0.72 | MAPT (0.74) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL4184589 | 0.71 | MAPT (0.55) | MAPTSMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL30360229 | 0.71 | MAPT (0.55) | MAPTSMN1; SMN2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122060811-A | Method for producing agricultural tryptophan by fermentation and application thereof | 烟台泓源生物肥料有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| WO-2025215232-A1 | A COMPOSITION COMPRISING A SAPONIN AND/OR AN ANTHELMINTIC AND/OR A MITOCHONDRIAL UNCOUPLER FOR THE TREATMENT OF LIVER DISEASE | RAINCASTLE BIO. LIMITED (GB) | 2025-10-16 | — | — | WO | claimed |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | claimed |
| WO-2024081653-A2 | METHODS OF LOWERING MIRO2 TO TREAT NEURODEGENERATIVE DISEASES | ACUREX BIOSCIENCES CORPORATION (US) | 2024-04-18 | — | — | WO | claimed |
| EP-4301759-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-01-10 | — | — | EP | claimed |
| US-11579152-B2 | Engineered hERG channel proteins, vesicles and methods of identifying small molecule pharmacological agents | THE ROCKEFELLER UNIVERSITY (US) | 2023-02-14 | — | — | US | claimed |
| US-20220389067-A1 | Methods of Treating Neurodegenerative Diseases Caused by G4C2 Expansion in C9ORF72 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-08 | — | — | US | claimed |
| WO-2022216386-A9 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-01 | — | — | WO | claimed |
| WO-2022216386-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2000006143-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. (US) | 2000-02-10 | — | — | WO | claimed |
| US-5994138-A | CONTAINS A STAIN CAPABLE OF LABELLING CELLS AFTER INCUBATION, AS WELL AS AN ADDITIVE WHICH IS ABLE TO ENCOURAGE PENETRATION OF THE STAIN INTO THE CELLS, THIS ADDITIVE BEING CHOSEN FROM AN IONOPHORIC COMPOUND, A DETERGENT AND MIXTURES THEREOF | ABX (FR) | 1999-11-30 | — | — | US | claimed |
| WO-1999059597-A1 | IONOPHORE CONTAINING COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1999-11-25 | — | — | WO | claimed |
| US-5981168-A | Method and composition for modulating amyloidosis | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1999-11-09 | — | — | US | claimed |
| EP-0856735-A1 | Colour staining reagent for blood cells | ABX (FR) | 1998-08-05 | — | — | EP | claimed |
| EP-0538302-B1 | REDUCTION OR PREVENTION OF SKIN IRRITATION BY DRUGS | ALZA CORP (US) | 1995-04-26 | — | — | EP | claimed |
| EP-0538302-A1 | REDUCTION OR PREVENTION OF SKIN IRRITATION BY DRUGS. | ALZA CORP (US) | 1993-04-28 | — | — | EP | claimed |
| US-5160741-A | Coadministering transdermally a time-release weak base drug and a lysosomal uptake inhibiting agent | ALZA CORPORATION (US) | 1992-11-03 | — | — | US | claimed |
| US-5130139-A | Coadministering lysosomac uptake inhibiting agent | ALZA CORPORATION (US) | 1992-07-14 | — | — | US | claimed |
| WO-1992000746-A1 | REDUCTION OR PREVENTION OF SKIN IRRITATION BY DRUGS | ALZA CORPORATION (US) | 1992-01-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | CACNA1G, CACNA1H, CACNB2 | MAPT 3351/4885SMN1; SMN2 3149/4885MEN1 1661/4885 |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ATP5ME, MT-ATP6, ATP5MK | MAPT 4765/4885SMN1; SMN2 3552/4885MEN1 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.